Panel discussion on...
Pet Supplements
Rajiv Khatau
Managing Director, Lodaat Pharma

Member of AgroFOOD Industry Hi Tech's Scientific Advisory Board

Microbial Homeostasis Across Species: Shaping Health Outcomes for Pets and Their Owners
1A) There are a few key differences between the human and pet supplement industries that revolve around the central theme of variability. The human supplement industry exists with its own specific set of standards. In contrast, pet supplements are either classified as food or animal drugs without its own category. Compared to the human supplement industry, there are fewer guidelines on the types of claims a company can make and the amount of science that is needed to support them. Additionally, ingredient companies can maximize claims by focusing on generalizable parameters that can be applied to multiple species of animals. However, the physiology of a cat is not the same as the physiology of a horse or a dog.
1B) Species-specific data is incredibly important in developing ingredients for pets. The only way to get a true indication of how a certain species will react to a supplement in a real-world environment is to run a controlled, research trial. Each species has a different diet, different gut microbiome, and, ultimately, different metabolism. An active ingredient that provides strong benefits in dogs may not give hamsters the same benefit. Safety, tolerability, and dosing similarly can vary with metabolism and weight. Human data serves as an excellent starting point, but species-specific data provides validated, scientific backing.
1C) The humanization of pets is the biggest driver that we see in the pet supplement industry today. There are trends towards clean-label, fresh foods and away from highly processed meals that mirror the human food and supplement industries. Pet parents are certainly seeking foods and supplements that will improve their pets’ quality of life. However, we also need to bear in mind that human physiology is different from animal physiology, and what is healthy for us as humans may not have the same benefit for our pets. For example, avocados have high levels of fats that are considered heart-healthy in humans but can cause gastrointestinal distress in dogs and cats.
1D) As an ingredient manufacturer, quality is of paramount importance to us, so we focus first on purity then standardization and bioavailability. Regardless of whether our ingredients are food-grade or feed-grade, all our ingredients meet the highest standards for microbiology, heavy metals, and other contaminants. For pet supplements particularly, standardization and bioavailability hold the same importance as they do in the human dietary supplement industry. We want to make sure that our functional ingredients are having the intended effect and are being properly dosed. Matrices for pet food are also different from human supplements, so it is important to be cognizant of any matrix interactions that may confound functional benefits.
1E) Standards are changing in the pet supplement industry. As part of the humanization of pets, owners increasingly want food that mirrors or even exceeds the standard of food that they want for themselves. Organic, clean-label, sustainable, transparent, and natural ingredients are being increasingly prioritized, but these ingredients can come with a premium price. As an ingredient manufacturer, we work to align with our customers in the face of price sensitivity they are facing for their finished formulations.
1L) In the past few years, our team has seen the pet supplement industry follow the lead of the human dietary supplement industry. There has been interest in our established human dietary supplement ingredients now for healthy aging in the pet industry. A key trend in healthy aging is pet owners wanting to make sure that their pets are able to live healthy, active lifestyles as long as possible with maximum mobility. Anti-inflammatory agents like curcumin with increased bioavailability are being used in formulas to support bone and joint health. Secondly, the gut microbiome is an area of increased research and focus as well. Prebiotics, like high-resistance potato starch, probiotics, and postbiotics are being added to more formulations to improve long-term digestive health, immune support, and nutrient absorption.
4A) As the pet supplement industry continues to mature, we are going to see a demand for data that supports differentiation based on quality. Pet owners are looking for brands that answer the question, “Will this make my pet feel better and live a healthier lifestyle?” Published species-specific clinical data is a big factor, and branded ingredients with clinical data are going to play a large role in setting supplement brands apart by corroborating their scientific benefits. If an ingredient is “vet-recommended,” that will significantly boost trust with pet owners. Similarly, quality standards with independent third-party validation and certifications are going to be trusted more. Simply being, “feed grade” will no longer be enough. Supplement benefits need to be reliable and consistent in order for consumers to see the difference in their pets. At the end of the day, the humanization of pets bolsters the idea that our pets need just as much focus on wellness as we do with diets that will help them live long, healthy lives alongside the rest of their family.
4B) Consumer education is a huge part of the supplement industry right now – both human and pet. People want to know how they and their pets live healthy lives in parallel. Standardizing claim and quality language would improve consumer understanding in the industry. Having consistent definitions across the US, EU, and Canada would also support consumer confidence and minimize confusion on product classification. Establishing specific, validated, and clear claims on efficacy and quality that are backed by third-party testing and research will also go a long way in improving consumer trust.
In this Panel Discussion, several prominent companies within the food and nutraceutical ingredient industry have been invited to discuss about drivers and barriers of healthy lifestyle, focusing on global and regional consumer trends, scientific achievements, emerging delivery formats, use of AI technologies and the implementation of the United Nations sustainability goals.
Panelists
References and notes
- Trinh P, Zaneveld JR, Safranek S, Rabinowitz PM. One health relationships between human, animal, and environmental microbiomes: a mini-review. Frontiers in public health. 2018 Aug 30;6:235.
- Simonis J. The microbial web: Exploring the interconnection between microbiome, human and planetary health. Journal of the Australasian College of Nutritional and Environmental Medicine. 2022 Jan 1;41(3):8-15.
- Kappala S. The gut microbiome and health of companion animals: Insights into physiology, dysbiosis and disease association.
- Hernandez J, Rhimi S, Kriaa A, Mariaule V, Boudaya H, Drut A, Jablaoui A, Mkaouar H, Saidi A, Biourge V, Borgi MA. Domestic environment and gut microbiota: lessons from pet dogs. Microorganisms. 2022 Apr 30;10(5):949.
- Skoufos S, Stavropoulou E, Tsigalou C, Voidarou C. Microbial Interconnections in One Health: A Critical Nexus Between Companion Animals and Human Microbiomes. Microorganisms. 2025 Jul 3;13(7):1564.
- Marsella R, De Benedetto A. Atopic dermatitis in animals and people: an update and comparative review. Veterinary sciences. 2017 Jul 26;4(3):37.
- Suarez L, Bautista-Castaño I, Peña Romera C, Montoya-Alonso JA, Corbera JA. Is dog owner obesity a risk factor for canine obesity? a “one-health” study on human–animal interaction in a region with a high prevalence of obesity. Veterinary Sciences. 2022 May 22;9(5):243.
- Mäki JM, Kirjavainen PV, Täubel M, Piippo-Savolainen E, Backman K, Hyvärinen A, Tuoresmäki P, Jayaprakash B, Heinrich J, Herberth G, Standl M. Associations between dog keeping and indoor dust microbiota. Scientific Reports. 2021 Mar 5;11(1):5341.
- Ma LC, Zhao HQ, Wu LB, Cheng ZL, Liu C. Impact of the microbiome on human, animal, and environmental health from a One Health perspective. Science in One Health. 2023 Jan 1;2:100037.
- Cui W, Cui Y, Hao Y, Li Y, Wang Y, Liu F, Long J, Jin Y, Chen S, Duan G, Yang H. The effect of pet dog exposure on gut antibiotic resistome and microbiome of their owners. Journal of Hazardous Materials. 2026 Feb 8:141429.
- Hesselmar B, Hicke-Roberts A, Lundell AC, Adlerberth I, Rudin A, Saalman R, Wennergren G, Wold AE. Pet-keeping in early life reduces the risk of allergy in a dose-dependent fashion. PloS one. 2018 Dec 19;13(12):e0208472.
- Indolfi C, D’Addio E, Bencivenga CL, Rivetti G, Bettini I, Licari A, Manti S, Mori F, Miraglia del Giudice M, Klain A. The primary prevention of atopy: does early exposure to cats and dogs prevent the development of allergy and asthma in children? A comprehensive analysis of the literature. Life. 2023 Sep 2;13(9):1859.
Questions
1.
2.
3.
4.
Ingredients companies - clinical data
A) What are the main scientific gaps that still exist in PET supplement development compared to human dietary supplements?
B) How important is species-specific research when selecting and developing active ingredients for pets? Can human data ever be sufficient?
C) Is the humanization of pets helping consumers make better-informed choices, or does it risk creating unrealistic expectations about supplement performance?
D) From an ingredient supplier’s perspective, which quality parameters (standardization, bioavailability, purity) are most critical for PET applications?
E) How are trends such as “clean label,” sustainability, and transparency influencing pet owners’ purchasing decisions in the PET supplement space?
F) What type of clinical evidence should realistically be expected to support PET supplement claims today?
G) Which types of claims are most likely to be misunderstood by consumers, and how can this risk be reduced through clearer substantiation and labeling?
H) What are the main methodological challenges in conducting clinical trials for companion animals, and how can they be addressed?
I) How reliable are owner-reported outcomes compared to veterinary assessments, and how should they be integrated into study design?
L) Have you noticed an increasing trend in the use of one (or more) ingredients for pet supplements formulated to promote healthy ageing?
Formulation
A) What are the biggest formulation challenges in PET supplements, particularly regarding palatability, stability, and dosing accuracy?
B) How do formulation choices (e.g., chews, powders, liquids) influence compliance and consistent use from a consumer perspective?
C) Do you see a shift toward simpler, single-ingredient formulations, or are multi-active blends still the dominant approach? Why?
D) How do species differences (dogs vs cats, size, age) influence formulation strategies?
E) Omega 3 alternatives for pet nutrition and sustainability: how do the innovative omega-3s for pet food stack up against their traditional fishy counterparts?
Regulation
A) How do regulatory frameworks for PET supplements differ between the EU and the US, and what challenges do these differences create for global brands?
B) Which types of claims represent the highest regulatory risk today, and which are more likely to be acceptable if properly substantiated?
C) Do you expect regulatory oversight of PET supplements to become stricter in the coming years? Why or why not?
D) What role should veterinarians play in guiding pet owners’ choices regarding PET supplements, and how can trust between brands, vets, and consumers be strengthened?
Open questions
A) Looking ahead 5–10 years, what will be the key factors determining the credibility and long-term success of the PET supplements sector?
B) In your view, what single change—scientific, regulatory, or educational—would most improve consumer trust in PET supplements over the next decade?
References and notes










